Altered distribution of RhoA in Alzheimer’s disease and AβPP overexpressing mice
Open accessAbstract
RhoGTPases control cytoskeleton dynamics thereby modulating synaptic plasticity. Because Alzheimer's disease (AD) is characterized by synaptic dysfunction, we sought to determine whether the expression, activity, or localization of the GTPases RhoA, Rac1 and Cdc42, as well as p21-PAK, a downstream target of Rac1/Cdc42, were altered in 18-month-old AbetaPP Tg2576 mice (Swedish mutation) or in brains from patients with AD and, for comparison in the case of RhoA, Pick's disease (PiD), a neurodegenerative disorder characterized by hyper-phosphorylated tau accumulation. Immunohistochemical analyses revealed a distinct localization of each RhoGTPase in synapses, dendrite shafts, neuronal bodies, or astrocytes. The association of RhoA with synapses and dendritic microtubules was confirmed by electron microscopy. In AbetaPP mice, RhoA expression decreased in synapses and increased in dystrophic neurites, suggesting altered subcellular targeting of RhoA. In AD, RhoA immunostaining decreased in the neuropil and markedly increased in neurons, co-localizing with hyperphosphorylated tau inclusions, as though RhoA were sequestered by neurofibrillary tangles. Additionally, total RhoA protein was lower in the AD brain hippocampus, reflecting loss of the membrane bound, presumably active, GTPase. RhoA colocalized with hyperphosphorylated tau in PiD, again suggesting that altered subcellular targeting of RhoA is related to neurodegeneration. No major immunohistochemical changes were observed for Rac1, Cdc42, or p21-PAK, thus identifying RhoA among RhoGTPases as a possible therapeutic target in AD.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Overall RhoA levels are reduced in human AD brains, while remaining RhoA colocalizes with hyperphosphorylated tau in NFTs.
“Overall RhoA levels were reduced in human AD brains, while remaining RhoA colocalized with hyperphosphorylated tau in NFTs [185].”
From RhoA Signaling in Neurodegenerative Diseases (2022) · cites this paper as [185]
Our indexed copy contains a title page (p. 1) and supplementary captions about APP mice (p. 2), but no findings on RhoA levels in human AD brains or RhoA colocalization with hyperphosphorylated tau in NFTs. Searches for those terms returned no relevant passage; the decisive main-text findings appear to be missing from the indexed copy. (LLM, conf=0.75)
Experimental — accuracy not yet measuredIn APP-overexpressing transgenic mouse brains, RhoA expression is decreased within synapses but increased in degenerating neurites.
“Moreover, in Aβ precursor protein (APP)-overexpressing transgenic mouse brains, RhoA expression was decreased within synapses but increased in degenerating neurites [185], suggesting that RhoA mislocation is related to neurodegeneration.”
From RhoA Signaling in Neurodegenerative Diseases (2022) · cites this paper as [185]
The available copy shows the title (p. 1) and supplementary findings about synaptophysin, PSD95, and PAK in APP mice (p. 2), but no findings about RhoA within synapses or degenerating neurites. Searches for RhoA expression and synaptic or neuritic redistribution returned no decisive passage; the apparent absence of the main results prevents verification. (LLM, conf=0.72)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cited by
Sorted by citations
Impaired Wnt Signaling in the Prefrontal Cortex of Alzheimer’s Disease
Folke, J., Pakkenberg, B., & Brudek, T. (2019) · Molecular Neurobiology · doi:10.1007/s12035-018-1103-z · Cited by 123 · see citing works
RhoA Signaling in Neurodegenerative Diseases
Schmidt, S. I., Blaabjerg, M., Freude, K., & Meyer, M. (2022) · Cells · doi:10.3390/cells11091520 · Cited by 110 · see citing works
Desale, S. E., Chidambaram, H., & Chinnathambi, S. (2021) · Molecular Biomedicine · doi:10.1186/s43556-021-00036-1 · Cited by 99 · see citing works
Rho GTPases in neurodegeneration diseases
DeGeer, J., & Lamarche-Vane, N. (2013) · Experimental Cell Research · doi:10.1016/j.yexcr.2013.06.016 · Cited by 46 · see citing works
Regulation of Small GTPase Prenylation in the Nervous System
Reddy, J. M., Raut, N. G. R., Seifert, J. L., & Hynds, D. L. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-01870-0 · Cited by 23 · see citing works
- Authors
- Huesa, G., Baltrons, M. A., Gómez-Ramos, P., Morán, A., García, A., Hidalgo, J., Francés, S., Santpere, G., Ferrer, I., & Galea, E.
- Affiliations
- Universitat Autònoma de Barcelona (ES)
- Institut de Biotecnologia i Biomedicina “Villar Palasí”, Departament de Bioquímica i Biologia Cellular, Universitat Autònoma de Barcelona, Spain
- Departamento de Anatomía, Histología y Neurociencia, Universidad Autónoma de Madrid, Spain
- Universidad Autónoma de Madrid (ES)
- Institut de Neurociènces, Universitat Autònoma de Barcelona, Spain
- Bellvitge University Hospital (ES)
- Institut de Neuropatologia, Servei d'Anatomia Patològica, Hospital Universitari de Bellvitge, Universitat de Barcelona, Hospitalet de Llobregat, CIBERNED, Spain
- Institució Catalana de Recerca i Estudis Avançats (ES)
- Corresponding author
- Galea, Elena
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2010-01-06
- Volume
- 19
- Issue
- 1
- Pages
- 37-56
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W1541377218
- Cited by
- 82
- References
- 0
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 7 · 2023: 6 · 2022: 3 · 2021: 7 · 2020: 8 · 2019: 4 · 2018: 4 · 2017: 8 · 2015: 7 · 2014: 3 · 2013: 5 · 2012: 2
- FWCI
- 3.25
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Alzheimer s Disease (publishedVersion)
- PubMed (publishedVersion)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- RhoA, Alzheimer's disease
- MeSH terms
- Alzheimer Disease, Animals, Inclusion Bodies, Humans, Male, Mice, Inbred C57BL, Mice, Transgenic, Phosphorylation, Synapses, Down-Regulation, Up-Regulation, Neurites, Amyloid beta-Protein Precursor, Neurofibrillary Tangles, tau Proteins, rhoA GTP-Binding Protein, Pick Disease of the Brain, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review